Business Context and Reporting Period
This Form 8-K is a current report filed by Magenta Therapeutics, Inc. on November 19, 2018. The filing discloses the appointment of a new executive officer and details the associated employment agreement. Note: The request metadata references "Dianthus Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Magenta Therapeutics, Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the appointment of Jason Ryan as Chief Operating and Financial Officer, effective January 1, 2019. Mr. Ryan previously served as Chief Financial Officer of Foundation Medicine, Inc. (a subsidiary of Roche Holdings, Inc.).
Guidance, Outlook, and Compensation Details
The filing outlines the specific terms of Mr. Ryan's Employment Agreement:
- Base Salary: $400,000 annually.
- Sign-on Bonus: One-time payment of $25,000.
- Performance Bonus: Targeted at up to 40% of the annual base salary, pro-rated to the start date.
- Equity Grant: Option to purchase 329,379 shares of common stock, subject to Compensation Committee approval.
- Severance (Termination without cause/Good reason):
- Standard: 0.75x base salary plus up to 9 months of COBRA contributions.
- Within 12 months of Change of Control: 1.0x (base salary + target bonus), 100% acceleration of equity awards, and up to 12 months of COBRA contributions.
The filing states there are no other arrangements or transactions requiring reporting under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the exact start date of the new COO/CFO (January 1, 2019) and the effective date of the employment agreement.
- Confirm the approval status of the 329,379 stock option grant by the Compensation Committee.
- Review the full text of the Employment Agreement (Exhibit 99.1) for specific definitions of "cause," "good reason," and "change in control."
- Check subsequent filings for any updates regarding the company's financial status, as this 8-K contains no operational or financial metrics.